Platform trials for rare cancers-A complex innovation to accelerate knowledge
- PMID: 39006529
- PMCID: PMC11241356
- DOI: 10.1093/nop/npae035
Platform trials for rare cancers-A complex innovation to accelerate knowledge
Conflict of interest statement
None declared.
Comment in
- doi: 10.1093/nop/npae001
References
-
- Alexander BM, Ba S, Berger MS, et al.; GBM AGILE Network. Adaptive global innovative learning environment for glioblastoma: GBM AGILE. Clin Cancer Res. 2018;24(4):737–743. - PubMed
-
- Dhaenens BAE, Heimann G, Bakker A, et al.. Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis: a potential model for rare diseases. Neurooncol. Pract. 2024;11(4):395–403.
-
- Scavone C, di Mauro G, Pietropaolo M, et al.. The European clinical trials regulation (No 536/2014): changes and challenges. Expert Rev Clin Pharmacol. 2019;12(11):1027–1032. - PubMed
Publication types
LinkOut - more resources
Full Text Sources